A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
about
KASL clinical practice guidelines: management of hepatitis CChronic hepatitis C: This and the new era of treatmentHepatitis C cirrhosis: New perspectives for diagnosis and treatmentNew era for management of chronic hepatitis C virus using direct antiviral agents: A reviewHCV Kinetic Models and Their Implications in Drug DevelopmentTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CSafety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Direct-acting antiviral agents and the path to interferon independence.Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 InfectionPreclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.Direct-acting antivirals for chronic hepatitis C.Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.Organic carbamates in drug design and medicinal chemistryDirect binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Ledipasvir/Sofosbuvir.Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in KoreaResistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Approaches to hepatitis C treatment and cure using NS5A inhibitorsNovel therapeutic approaches for hepatitis C.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
P2860
Q26752471-A7FFF7F9-B9E2-4CDF-A07C-4EAD76A2EBBAQ26775011-74539DFB-4889-4B10-9A14-B8EC5E5C1437Q26799924-59F2F9C9-EB80-4B68-9B10-DCCE5687182EQ26800050-A6A40090-CC4F-4F4C-942D-F86ED8E0C43DQ26801602-8F66165C-3012-4571-8284-65E1279DFAC3Q28070260-C4B49561-B688-46DB-A6BC-90A29F807D0BQ28076883-35E91B9D-991A-4B4D-AE22-6F1BA4E21F87Q28079102-DBDF4D9A-3888-4402-A15F-D0142B5658FBQ28080225-6164B2C0-9DC0-484A-9854-F8838C8EE75FQ31019494-D4852C66-9EBF-465F-BA5F-4E950F0CB36BQ31051529-7DCEB7AD-9836-4361-997D-1D09E7FC827AQ33727347-F40ADFCC-EEEB-4E67-8232-8A96CDB863A8Q33934312-9CA9A9E2-57B0-4F96-8AFB-8E9504992962Q34058093-02358266-7FF2-4FBE-8E55-2E5F6796EEAFQ34332546-A4D8FE0F-DCEF-4A30-8106-40F3074F6E2DQ34411617-B384814A-5EDF-4C44-9F3E-E571AD808364Q34454200-27986C67-3ADA-4268-A9E1-49EB05FC31AEQ34506788-91BE119C-35A4-444D-9691-C813FEE3B862Q34536770-FC0378C2-D330-407A-89F5-327B8FEEA29AQ34557595-96B3F0EF-29D9-442A-9004-6F719FC30740Q35048926-A1A57BB3-F44A-409B-83CA-488BD5861F17Q35365543-981933AB-A7F3-4314-B5E7-CA19DE7254A3Q35598309-1675A33F-D7AB-432A-8C9F-4F6A4DC71633Q35759025-3D7E3D65-75F0-4B8F-BD2A-8E2421DE54C5Q36052231-86240FF3-257A-4F76-A947-BC2F073E0362Q36100521-9F840C12-5695-4296-A167-3035A56D4D67Q36182240-6A93BF01-BE5B-4693-A442-4CEA7A8ECCD0Q36460249-AB85A081-A18B-4277-8FA5-A5C60CC2A4BAQ36558519-9572F161-F118-4D38-9CCA-C9C8DDB2F9B8Q36668891-BA6CA0D1-9603-4E13-B520-5037A380E9AAQ37263769-0FF7291F-7A64-495E-8CEA-555C443D384EQ37263870-CE764443-3A31-4370-A985-C2C8E1A58966Q37287839-1CCF9BA4-7E78-4744-822B-5804CA840FC2Q37426527-B6F80D52-9709-4951-B882-32917B09BFD3Q37630422-62563B41-D9E6-4A5B-AD87-DF824D0A377FQ38152674-3263D5DC-58A2-4513-AE9F-8AD01F93FB68Q38193198-C44C119C-213A-4EAB-8B58-A8C38BDA62BCQ38193551-11825A42-04C2-4706-9139-ADBE76280AC9Q38353529-2745C166-78AE-4E25-B42D-845AEF0CE198Q38375284-F5B0572B-7691-4166-A742-62F158A9F999
P2860
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@ast
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@en
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@nl
type
label
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@ast
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@en
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@nl
prefLabel
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@ast
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@en
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@nl
P2093
P1476
A phase 1, randomized, placebo ...... s with genotype 1 hepatitis C.
@en
P2093
Anita Mathias
Daniel Gruener
Diana M Brainard
Eric J Lawitz
Guofeng Cheng
Hongmei Mo
John G McHutchison
John M Hill
John O Link
Kelly A Wong
P356
10.1016/J.JHEP.2011.12.029
P577
2012-02-05T00:00:00Z